MENU
BVAXD
Stock ticker: OTC
PRICE
CHANGE
CAPITALIZATION
BioVaxys Technology (BVAXD) Ownership - Who owns BioVaxys Technology?
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
6.41M
P/E Ratio
N/A
Total Cash
N/A
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
N/A
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
BVAXD
Capitalization
6.41M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
N/A
Total Cash/Share
N/A
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
N/A
P/B Ratio
N/A
Cash Flow
N/A
Earnings
-0.2
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
N/A
Current Ratio
0.29
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-4.74M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-440.76
Shares Held By Institutions
N/A
Shares Outstanding - Current
29.3M
Total Liabilities
N/A
Total Volume MTD
N/A
Value
1
Gain YTD
-47.116
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information